Granules India Results Q4 FY 2021: Granules India, a vertically integrated pharmaceutical company, on Tuesday announced its financial results for the fourth quarter and full year ended 31st March 2021.
Commenting on Granules results, Mr. Krishna Prasad Chigurupati, Chairman & Managing Director of Granules India Limited said, “I am very pleased with the performance across all our segments and geographies during the year. Multiple product launches across portfolios helped us to deliver a record high growth of 25% in sales.
“We also delivered a strong growth in profit, which is up 64% YoY. Despite unprecedented challenges over the past year, our robust performance demonstrates the unwavering commitment of our colleagues and the resilience of our business. We are investing for the next phase of growth across all verticals. I remain confident in Granules India’s ability to continue to deliver on our stated goals to our stakeholders in FY2022 and thereafter, while remaining steadfast on ensuring the safety of our employees.”
Granules India FY21 Income from operations show a record growth – up 25% YoY, EBITDA at INR 855 Cr, up 63% YoY; PAT at INR 549 cr, up 64% YoY
FY21 income from operations at INR 3,238 Cr, record growth of 25% YoY. EBITDA stood at INR 855Cr, a growth of 63% YoY. EBITDA margins stood at 26%. PAT at INR 549 Cr a growth of 64%.
The company had posted a net profit of Rs 92.33 crore for the corresponding period of the previous fiscal, Granules India said.
Consolidated revenue from operations of the company stood at Rs 799 crore for the quarter under consideration. It was Rs 600 crore for the same period a year ago, it added.
For the financial year ended March this year, the company posted a net profit of Rs 549 crore as against Rs 335 crore for the previous financial year, Granules India said.
The company’s revenue from operations of the company stood at Rs 3,238 crore for the financial year under consideration. It was at Rs 2,599 crore for the previous financial year, it added.
